Clinical Trials Directory

Trials / Completed

CompletedNCT02361723

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation, and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
101 (actual)
Sponsor
BeiGene · Industry
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

The study contains Phase 1A and Phase 1B. Phase 1A has Part1 (BID Dose Escalation) and Part2 (QD Dosing Escalation) Evaluation of a cohort of at least three participants completing one cycle of treatment at that dose level and dose regimen is required prior to determining the next dose level and dose regimen for the next cohort. Phase 1B has PartA (BID Dosing Expansion) will investigate efficacy in participants with selected tumor types and further evaluate safety and tolerability of BGB 290 at recommended dose for future studies. and PartB (Food Effect) will investigate the food effect on the Pharmacokinetics (PK) of BGB 290 in participants with advanced solid tumors.

Detailed description

The study contains Phase 1A and Phase 1B. Phase 1A has Part1 (BID Dose Escalation) and Part2 (QD Dosing Escalation) Evaluation of a cohort of at least three participants completing one cycle of treatment at that dose level and dose regimen is required prior to determining the next dose level and dose regimen for the next cohort. Phase 1B has PartA (BID Dosing Expansion) will investigate efficacy in participants with selected tumor types and further evaluate safety and tolerability of BGB 290 at recommended dose for future studies. and PartB (Food Effect) will investigate the food effect on the PK of BGB 290 in participants with advanced solid tumors.

Conditions

Interventions

TypeNameDescription
DRUGBGB-290
DRUGBGB-290
DRUGBGB-290
DRUGBGB-290
DRUGBGB-290

Timeline

Start date
2014-07-03
Primary completion
2019-09-03
Completion
2019-09-03
First posted
2015-02-12
Last updated
2024-12-27

Locations

7 sites across 1 country: Australia

Source: ClinicalTrials.gov record NCT02361723. Inclusion in this directory is not an endorsement.